Objective Faecal microbiota transplantation (FMT) has proved to be an extremely effective treatment for recurrent Clostridioides difficile infection, and there is interest in its potential application in other gastrointestinal and systemic diseases. However, the recent death and episode of septicaemia following FMT highlights the need for further appraisal and guidelines on donor evaluation, production standards, treatment facilities and acceptable clinical indications.
Design For these consensus statements, a 24-member multidisciplinary working group voted online and then convened in-person, using a modified Delphi approach to formulate and refine a series of recommendations based on best evidence and expert opinion. Invitations to participate were directed to Australian experts, with an international delegate assisting the development. The following issues regarding the use of FMT in clinical practice were addressed: donor selection and screening, clinical indications, requirements of FMT centres and future directions. Evidence was rated using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system.
Results Consensus was reached on 27 statements to provide guidance on best practice in FMT. These include: (1) minimum standards for donor screening with recommended clinical selection criteria, blood and stool testing; (2) accepted routes of administration; (3) clinical indications; (4) minimum standards for FMT production and requirements for treatment facilities acknowledging distinction between single-site centres (eg, hospital-based) and stool banks; and (5) recommendations on future research and product development.
Conclusions These FMT consensus statements provide comprehensive recommendations around the production and use of FMT in clinical practice with relevance to clinicians, researchers and policy makers.
- faecal microbiota transplantation
- Clostridioides difficile
- inflammatory bowel disease
- microbiome therapeutics
- stool bank
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors CH, SP, DA and RWL were members of the steering committee which formulated the initial statements, completed the literature review, refined statements between each round of voting and allocated statements to delegates. All authors voted on statements and were responsible for reviewing and presenting the literature surrounding their designated statement. CH, CRK, SP, DA, LEP, HS and RWL were part of the manuscript committee which formulated the final manuscript. All authors reviewed the manuscript and approved the final version.
Funding This study was conducted using internal research funds through the University of Sydney.
Competing interests CRK has received research support and is a site investigator for Finch Therapeutics; and is a clinical advisory board member for Openbiome. SP is a consultant for Finch Therapeutics and received speaker fees from Ferring, Janssen. TJB has interest in Redhill Biopharma, Salix and Finch Therapeutics, ResMed and GSK; has interest in the Centre for Digestive Diseases, where faecal microbiota transplantation is a treatment option for patients, and has patents in this field. MK has received speaker fees, research funding, educational support or honoraria for advisory board participation from Ferring, AbbVie, Janssen, Takeda and received research support from AbbVie. SPC has received speaker fees from Shire, Ferring, Microbiotica, Pfizer and Janssen; and is a shareholder in BiomeBank. JMA has received speaker fees, research funding, educational support or honoraria for advisory board participation from Abbott, AbbVie, Allergan, Anatara, AstraZeneca, Bayer, Celegene, Ferring, Gilead, Hospira, Immuninc, ImmunsanT, Janssen, MSD, Nestle, Progenity, Pfizer, Shire, Takeda, Vifor, Royal Adelaide Research Fund and The Hospital Research Fund. JB has received speaker fees, research funding, educational support or honoraria for advisory board participation from Janssen, Takeda, AbbVie, Celgene, Ferring, Pfizer, Anatara, Microba, Shire and Progenity. SC has received speaker fees, research funding, educational support or honoraria for advisory board participation from AbbVie, Aspen/Orphan, Celgene, Ferring, Gilead, Janssen, MSD, Pfizer, Shire, Takeda and Vifor. SG has received speaker fees, research funding, educational support or honoraria for advisory board participation from Janssen Cilag, Shire, Takeda, Ferring and Pfizer and AbbVie. DAL has received speaker fees, research funding, educational support or honoraria for advisory board participation from Nutricia, Nestle, Janssen, AbbVie. RP has received speaker fees or research support from Janssen, Aspen, Pfizer, Abbvie and Takeda. RWL reports advisory board fees from AbbVie, Aspen, Celgene, Ferring, Gilead, Hospira, Janssen, MSD, Novartis, Pfizer, and Takeda; research fees from Gastrointestinal Society of Australia (GESA), Endochoice, Janssen, National Health and Medical Research Council of Australia, Shire, and Takeda; and speaker fees from Emerge Health, Ferring, Janssen, Shire, and Takeda.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement There are no data in this work